The American Journal of GASTROENTEROLOGY see related editorial on page x REVIEW CLINICAL AND SYSTEMATIC REVIEWS INTRODUCTION Hepatocellular carcinoma (HCC) is the fi ft h most common cause of cancer and the third leading cause of cancer-related death worldwide ( 1 ). Within the United States and Europe, its increasing incidence is largely driven by the current epidemic of hepatitis C virus (HCV) cases; however, nonalcoholic fatty liver disease (NAFLD) is an increasingly common etiology for cirrhosis and HCC ( 1 ). Furthermore, the metabolic syndrome and hepatic steatosis are well-recognized cofactors in patients with other liver diseases, such as those with viral hepatitis. Underlying cirrhosis is the strongest risk factor for HCC development, and HCC is one of the leading causes of death among patients with cirrhosis.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fi ft h most common cause of cancer and the third leading cause of cancer-related death worldwide ( 1 ) . Within the United States and Europe, its increasing incidence is largely driven by the current epidemic of hepatitis C virus (HCV) cases; however, nonalcoholic fatty liver disease (NAFLD) is an increasingly common etiology for cirrhosis and intake ( 2 ) . In addition, family history and ethnicity are risk factors for HCC, suggesting a possible genetic component to the development of HCC. Although genome-wide association and candidate gene studies have started to explore this area, the role of genetic factors in HCC development remains poorly understood ( 3 ) .
PNPLA3, also known as adiponutrin, is a member of the patatinlike phospholipase family. Th e rs738409 C → G single-nucleotide polymorphism (SNP), encoding the Ile 148Met variant protein of PNPLA3, is a well-described genetic determinant of hepatic steatosis ( 4 ) . Several studies have established a strong link between PNPLA3 and the development of NAFLD ( 5 ) . Th e rs738409 SNP has also recently been associated with fi brosis severity and HCC risk in patients with known liver disease. Th e purpose of this meta-analysis is to evaluate the association between PNPLA3 and (i) liver fi brosis severity among patients with liver disease, (ii) the development of HCC among patients with cirrhosis, and (iii) prognosis among patients with HCC.
METHODS

Literature search
We conducted a computer-assisted search with the Ovid interface to Medline, PubMed, Scopus, and Embase databases to identify relevant published articles. We searched the databases from inception through 1 May, 2013 with the following keyword combinations: " PNPLA3 or adiponutrin " . Manual searches of reference lists from applicable studies were performed to identify any studies that may have been missed by the computer-assisted search. Additional searches of Digestive Diseases Week, American Association for the Study of Liver Diseases, European Association for the Study of the Liver (EASL), International Liver Cancer Association, and American College of Gastroenterology meeting abstracts from 2010 to 2012 were performed. Finally, consultation with expert hepatologists was done to identify additional references or unpublished data. Th is study was conducted in accordance with the PRISMA guidelines ( 6 ) .
Study selection
Two investigators (A.G.S. and H.M.) reviewed all titles of citations identifi ed by the search strategy to generate a list of potentially relevant articles. Th e abstract for each potentially relevant study was then reviewed by each of the two investigators. If the applicability of a study could not be determined by title or abstract alone, the full text was reviewed. Th e articles were independently checked for possible inclusion and any disagreements were resolved through consensus with a third investigator (J.A.M.).
Study inclusion and exclusion criteria
Studies were included for analysis if they (i) included patients with underlying liver disease, (ii) reported stage of fi brosis, HCC incidence, and / or HCC prognosis, and (iii) stratifi ed outcomes according to PNPLA3 genotype. We excluded studies that (i) included patients without liver disease (e.g. a cohort of obese patients), (ii) assessed outcomes in a pediatric population, (iii) assessed outcomes in post-transplant patients, or (iv) only included data regarding liver enzymes, hepatic steatosis, or infl ammatory activity but not stage of fi brosis. Additional exclusion criteria included nonhuman data, lack of original data, and incomplete reports. If publications used the same cohort of patients, the manuscript with the most complete data was included.
Data extraction
Two reviewers (A.G.S. and H.M.) independently reviewed and extracted the required information from eligible studies using standardized forms. A third investigator (J.A.M.) was available to resolve any discrepancies between the two sets of extracted data. Th e data extraction form included the following study design items: study methodology, size and characteristics of study cohort, and inclusion and exclusion criteria. We recorded the following primary data for patients according to PNPLA3 genotype: number of patients with advanced fi brosis, number of patients who developed HCC, and tumor stage. We attempted to obtain missing data by contacting authors of included studies. One investigator (A.G.S.) assessed study quality by a modifi ed checklist based on a modifi ed version of the Ottawa -Newcastle scale, and discrepancies were resolved by review with an independent investigator (A.K.W.). Th is instrument rates observational studies based on selection of study population, comparability of study groups, and adequacy of outcome assessment ( 7, 8 ) .
Clinical end points and statistical analysis
Th e primary outcomes analyzed were the odds of advanced fi brosis and the odds of developing HCC. For each individual study, an odds ratio (OR) for each outcome of interest was calculated according to PNPLA3 genotype, using both recessive (genotype GG vs. CG + CC) and dominant (genotype CC vs. CG + GG) genetic models. A pooled estimate with corresponding 95 % confi dence interval (CI) was estimated using the DerSimonian and Laird method for a random eff ects model.
Heterogeneity was initially evaluated graphically by examination of forest plots. Th e χ 2 -test of heterogeneity was used to statistically assess the presence of signifi cant heterogeneity and the inconsistency index ( I 2 ) was used to assess magnitude of heterogeneity ( 9, 10 ) . A χ 2 -test P value < 0.10 or I 2 values > 50 % are consistent with the possibility of substantial heterogeneity. In cases of statistical heterogeneity, meta-infl uence analysis, in which one study is removed at a time from the model was performed to determine if there was possible undue infl uence of a single study ( 11 ) . Publication bias was initially evaluated graphically by funnel plot analysis and then statistically by using Begg ' s test ( 12 ) . An asymmetric funnel plot could suggest the possibility of small studies that were not published due to unfavorable results. Subset analyses were planned for predefi ned variables, including (i) location of study, (ii) etiology of underlying liver disease, and (iii) defi nition of advanced fi brosis.
RESULTS
Literature search
Th e computer-assisted search yielded 406 unique titles published through 1 May, 2013. Aft er initial review, 175 titles were Advanced fi brosis was signifi cantly associated with PNPLA3 polymorphism, with a similar strength of association between recessive and dominant genetic models. When assuming a recessive model, GG carriers were signifi cantly more likely to have advanced fi brosis than did those with CG or CC genotypes (OR 1.32, 95 % CI 1.20 -1.45; Figure 2 ). Meta-analysis with a fi xedeff ects approach yielded a similar association (OR 1.25, 95 % CI 1.16 -1.34). A dominant model yielded a pooled OR for advanced fi brosis of 1.29 (95 % CI 1.21 -1.38) for patients with CG or GG genotypes compared with those with CC genotype. On the basis of previous studies ( 28 ), a recessive model was used for subsequent analyses.
Th ere was no signifi cant heterogeneity among studies ( I 2 = 21.4 % , P = 0.17). We performed preplanned subset analyses, according to study location and etiology of underlying liver disease, using the random-eff ects recessive model. Th e eff ect of PNPLA3 on fi brosis was consistent among these subsets of patients. Th e eff ect of PNPLA3 on fi brosis was similar between studies conducted in Europe or the United States and those conducted elsewhere (OR 1.35, 95 % CI 1.21 -1.49 vs. OR 1.28, 95 % CI 0.95 -1.60, respectively). Th ere were also similar odds of having advanced fi brosis among patients with NAFLD or alcoholic liver disease than there were among those with other liver diseases (OR 1.23, 95 % CI 1.10 -1.37 vs. OR 1.44, 95 % CI 1.28 -1.61, respectively). Th e pooled OR for advanced fi brosis among the studies specifi cally evaluating HCV patients was 1.47 (95 % CI 1.27 -1.67).
Association between PNPLA3 rs738409 SNP and HCC
Nine studies, with a total of 2,937 patients, assessed the risk of HCC according to rs738409 genotype ( 29,41 -48 ) ( Table 2 ). We excluded one study addressing the impact of PNPLA3 on HCC risk, given the inclusion of patients without liver disease ( 49 ) . Six of the remaining nine studies were conducted solely in patients with underlying cirrhosis. All studies were conducted in Europe among Caucasian adult populations except for one study performed in Japan. Th ere have been six retrospective cohort studies, two case-control studies, and one prospective cohort study -all published in the past 2 years. Two studies included only patients with HCV, two assessed patients with NAFLD, one included alcohol-induced cirrhosis patients, and four studies had mixed cohorts.
HCC risk was signifi cantly associated with PNPLA3 polymorphism but the strength of this association depended on the genetic model. When assuming a recessive model, GG carriers were signifi cantly more likely to have HCC than did those with CG or CC (OR 1.45, 95 % CI 1.11 -1.80) ( Supplementary Figure ) . With the recessive model, we found signifi cant heterogeneity ( I 2 = 62.7 % , P = 0.006). Meta-analysis with a fi xed-eff ects approach yielded a similar association (OR 1.33, 95 % CI 1.15 -1.51). Among the six studies in which all patients had underlying cirrhosis, PNPLA3 continued to be associated with an increased risk of HCC (OR 1.58, 95 % CI 1.35 -1.81). Suffi cient data were available from six studies to assess a pooled OR for HCC assuming a dominant model. potentially appropriate. Each of these abstracts was reviewed, and an additional 83 studies were excluded. Ninety-two publications underwent full-text review, of which 32 met the inclusion criteria ( Figure 1 ). Searches of annual meeting abstracts yielded one relevant abstract, producing a total of 33 studies, with a total of 12,735 patients, for inclusion in the meta-analysis.
Effect of PNPLA3 rs738409 SNP on fi brosis severity
A total of 24 studies, with 9,915 patients, assessed the eff ect of PNPLA3 rs738409 genotype on liver fi brosis severity ( 13 -36 ) ( Table 1 ) . We excluded other studies addressing the impact of PNPLA3 on fi brosis severity given the inclusion of patients without liver disease ( 37, 38 ) , the lack of a gold standard to assess fi brosis ( 39 ) , and the use of overlapping cohorts with included publications. We also excluded a publication by Clark et al. ( 40 ) given that they assessed the rs2896019 polymorphism of PNPLA3 instead of rs738409. In brief, this SNP was associated with advanced fi brosis, defi ned as bridging fi brosis, under a dominant genetic model ( P = 0.04) but not a recessive ( P = 0.70) or additive model ( P = 0.09).
All included articles were published in the past 5 years and most were conducted in Europe or the United States, enrolling primarily Caucasian patients, with only four being conducted elsewhere (Malaysia, Argentina, Turkey, and Japan). All studies were crosssectional in nature, assessing the severity of fi brosis at only one point in time. Eleven studies included patients with HCV infection, seven evaluated NAFLD patients, three had patients with alcoholic cirrhosis, one included those with hemochromatosis, and two studies had mixed cohorts. We did not fi nd any evidence 
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cirrhosis and HCC ( 47 ) . Patients had a combination of liver diseases, although most had NAFLD ( n = 57) or alcoholic liver disease ( n = 34). Th e PNPLA3 SNP was associated with larger tumors (median 3.8 vs. 2.8 cm, P = 0.047), although there was no signifi cant diff erence in tumor, node, metastases staging ( P = 0.21). Valenti et al. ( 50 ) assessed 265 patients with cirrhosis and HCC and found a direct association between tumor size and the PNPLA3 rs738409 SNP, assuming an additive genetic model, although this did not achieve statistical signifi cance ( P = 0.06). On Cox regression, the PNPLA3 SNP alleles were associated with a nonsignifi cant higher risk of death (hazard ratio 1.39, 95 % CI 0.94 -2.02), independent of age, gender, etiology of liver disease, and smoking status.
Quality assessment
Th e quality assessment for included studies is described in Table 4 . All studies adequately ascertained PNPLA3 exposure and outcomes (of advanced fi brosis or HCC development), through medical records. Although all studies assessing HCC outcomes had representative cohorts, several studies assessing fi brosis outcomes had convenience samples that may not be representative of larger populations. For example, most studies assessing fi brosis in HCV patients only included those who were undergoing pretreatment biopsy, which may underrepresent patients with morbid obesity or other signifi cant medical comorbidities. Similarly, most studies only included patients undergoing biopsy for clinical purposes, thereby excluding any patients with cirrhosis and overt hepatic decompensation. Th ere is only one study by Dunn et al. ( 14 ) that attempts to assess this association from a population basis, using autopsy data ( 14 ) . Furthermore, we found that several studies also A dominant model yielded pooled OR of 1.40 (95 % CI 1.12 -1.75) for patients with CG or GG genotypes compared with those with CC genotype, without signifi cant statistical heterogeneity ( I 2 = 45.5 % , P = 0.10; Figure 3 ). We also performed preplanned subset analyses, according to study location and etiology of underlying liver disease, using the random eff ects dominant model. Th e one study conducted outside of Europe, by Takeuchi et al. ( 47 ) , had a similar point estimate for HCC risk compared with the others conducted in Europe (OR 1.45, 95 % CI 1.15 -1.83). However, the eff ect of PNPLA3 on HCC risk appeared to be dependent on liver disease etiology. Among the subset of patients with NAFLD or alcohol abuse, PNPLA3 continued to be associated with increased odds of HCC (OR 1.67, 95 % CI 1.27 -2.21). However, the association between PNPLA3 CG or GG genotype and HCC was not statistically signifi cant among patients with other causes of cirrhosis, including HCV (OR 1.33, 95 % CI 0.96 -1.82).
HCC prognosis
Th ree studies included extractable data about HCC prognosis according to rs738409 genotype ( Table 3 ) ( 42, 47, 50 ) . As each study used diff erent surrogates of prognosis, we were not able to pool the results for the meta-analysis. Faletti and colleagues ( 42 ) Stattermayer (2011) Rembeck (2012) Miyashita (2012) Dunn (2012) Zampino (2013) Rotman (2010) Stickel (2011) Vigano (2013) Valenti (2011) Burlone (2012) Trepo (2011) Krawczyk (2011) Valenti (2012) Guichelaar (2013) Muller (2011) Way (2013) Zain (2012) Trepo (2011) Valenti (2011) Stattermayer (2012) Patin (2011) Payer (2012) Idilman (2012) Hotta (2010 failed to control for important confounders, such as age, gender, and alcohol intake for presence of signifi cant fi brosis or presence of cirrhosis, age, and gender for development of HCC.
DISCUSSION
Our meta-analysis highlights the point that PNPLA3 ' s role is not limited to the development of hepatic steatosis and NAFLD, as it also appears to eff ect subsequent progression to advanced fi brosis and the development of HCC. We demonstrated that PNPLA3 rs738409 is associated with fi brosis severity among patients with underlying liver disease and that it is an independent risk factor for HCC among those with cirrhosis. We did not fi nd any evidence for an association between PNPLA3 genotype and HCC prognosis; however, larger studies with a wide distribution of tumor stages are still needed. Valenti (2011) Nischalke (2012) Liu (2013) 1.40 (1.12, 1.75) ( 59, 60 ) . Although racial / ethnic diff erences in NAFLD and HCC incidence could be attributed to the frequency of PNPLA3 variants, it is alternatively possible that race and / or ethnicity could moderate the risk of these outcomes associated with the PNPLA3 variant ( 4 ) .
High quality studies, including retrospective and prospective cohort studies, have established an association between PNPLA3 and HCC risk. However, all studies to date assessing fi brosis severity according to PNPLA3 genotype have been cross-sectional in nature. Trepo et al. ( 26 ) estimated a fi brosis progression rate by using the ratio of fi brosis stage at diagnosis and estimated duration of disease. When dichotomizing patients by the median progression rate, PNPLA3 was associated with fi brosis progression using a recessive model (OR 2.65, 95 % CI 1.28 -5.51). However, longitudinal studies, preferably with an assessment of fi brosis at several time points, are still needed. Furthermore, higher quality studies with more representative sampling of at-risk patients are still needed.
In summary, the PNPLA3 rs738409 C → G SNP is associated with a signifi cantly increased risk of both advanced fi brosis and HCC among patients with liver disease. In the age of personalized medicine using genetic determinants, PNPLA3 may help defi ne a subgroup of patients toward whom future interventions, such as weight loss techniques and / or HCC surveillance, should be directed. An improved understanding of the biological role of PNPLA3, as well as its interactions with other genes and proteins, could potentially lead to the development of therapeutic targets to reduce the risk of fi brosis progression and / or HCC susceptibility.
Although its exact biological function is debated, PNPLA3 is highly expressed on the surface of lipid droplets of hepatocytes and adipose tissue ( 51 ) . Th e rs738409 variant appears to interfere with lipoprotein export as well as to favor lipogenic activity over lipase activity, leading to hepatic fat accumulation ( 51 -53 ) . We found that PNPLA3 was associated with an increased risk of signifi cant fi brosis, independent of liver disease etiology. Patients with steatosis, either due to NAFLD or alcohol abuse, had the same increased odds of having signifi cant fi brosis as did those with other causes of liver disease, including HCV infection. However, it should be noted that most included studies assessed either NAFLD or HCV infection, with only one study assessing HBV infection and another assessing patients with hemochromatosis. Further studies assessing the association between PNPLA3 and the presence of advanced fi brosis in other liver disease etiologies are still needed.
Furthermore, the exact mechanism behind this association remains poorly understood. PNPLA3 does not appear to exert any direct association on HCV, as there is no known eff ect on viral load or treatment response ( 54 ) . It is possible that this association is simply related to confounders, such as increased fi brosis from concomitant alcohol abuse or metabolic syndrome, among patients with PNPLA3 GG genotype. Supporting this hypothesis, M ü ller and colleagues ( 19 ) found that PNPLA3 ' s eff ect on fi brosis was restricted to those who had signifi cant alcohol abuse. HCV-positive patients with signifi cant alcohol use had 4.8-odds (95 % CI 1.39 -6.38) of having cirrhosis, compared with only 1.65-odds (95 % CI 0.54 -5.03) in abstainers with HCV infection ( 19 ) . Unfortunately, few other studies report rates of alcohol abuse and / or metabolic syndrome among the PNPLA3 genotypes to replicate this analysis.
Only a small fraction of patients with HCV or NAFLD progress to cirrhosis and / or HCC ( 55 ) . Studies using clinical risk factors alone to predict fi brosis severity and / or HCC development have been limited by modest accuracy, and inclusion of genetic risk factors may enhance risk stratifi cation ( 56 ) . It is possible that risk factors, including genetic factors such as PNPLA3, may be diff erent according to liver disease etiology. For example, we found that PNPLA3 was associated with increased HCC risk in patients with nonalcoholic steatohepatitis or alcohol-related cirrhosis but not in patients with HCV-related cirrhosis. Th is fi nding may simply be related to smaller sample sizes in subset analyses; however, it may suggest diff erential mechanisms of hepatocarcinogenesis according to liver disease etiology. Identifi cation of high-risk patients could better defi ne a subgroup of patients, in whom liver function should be closely monitored and at whom interventions should be tar- 
